{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:34Z","timestamp":1792839694939,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"crossref","award":["1 U54 DK083909"],"award-info":[{"award-number":["1 U54 DK083909"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"crossref","award":["5UL1TR001420"],"award-info":[{"award-number":["5UL1TR001420"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"crossref","award":["UL1RR029876"],"award-info":[{"award-number":["UL1RR029876"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10620-023-07859-8","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T15:04:10Z","timestamp":1677078250000},"page":"2738-2746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ledipasvir\/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C"],"prefix":"10.1007","volume":"68","clinical-trial-number":[{"clinical-trial-number":"nct03118674","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-3230","authenticated-orcid":false,"given":"Herbert L.","family":"Bonkovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Rudnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Overbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Hallberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli","family":"Hedstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetanshi","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshata","family":"Moghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"7859_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cphy.c120006","volume":"3","author":"HL Bonkovsky","year":"2013","unstructured":"Bonkovsky HL, Guo J-T, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3:365\u2013401.","journal-title":"Compr Physiol."},{"key":"7859_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"DM Bissell","year":"2017","unstructured":"Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med 2017;377:862\u2013872.","journal-title":"N Engl J Med"},{"key":"7859_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hep4.1297","volume":"3","author":"B Wang","year":"2019","unstructured":"Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: Review and recent progress. Hepatol Commun 2019;3:193\u2013206.","journal-title":"Hepatol Commun"},{"key":"7859_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF00412489","volume":"278","author":"F Sixel-Dietrich","year":"1985","unstructured":"Sixel-Dietrich F, Doss M. Hereditary uroporphyrinogen-decarboxylase deficiency predisposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral contraceptive medication. Arch Dermatol Res 1985;278:13\u201316.","journal-title":"Arch Dermatol Res"},{"key":"7859_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ymgme.2018.11.013","volume":"128","author":"Y Weiss","year":"2019","unstructured":"Weiss Y, Chen B, Yasuda M, Nazarenko I, Anderson KE, Desnick RJ. Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations. Mol Genet Metab 2019;128:363\u2013366.","journal-title":"Mol Genet Metab"},{"key":"7859_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/ckj\/sfx146","volume":"11","author":"N Pallet","year":"2018","unstructured":"Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J 2018;11:191\u2013197.","journal-title":"Clin Kidney J"},{"key":"7859_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","volume":"10","author":"AK Singal","year":"2012","unstructured":"Singal AK, Kormos-Hallberg C, Lee C et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012;10:1402\u20131409.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7859_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1478-3231.2012.02794.x","volume":"32","author":"FR Caballes","year":"2012","unstructured":"Caballes FR, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012;32:880\u2013893.","journal-title":"Liver Int"},{"key":"7859_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.amjms.2017.03.007","volume":"353","author":"AK Singal","year":"2017","unstructured":"Singal AK, Venkata KVR, Jampana S, Islam F-U, Anderson KE. Hepatitis C treatment in patients with porphyria cutanea tarda. Am J Med Sci 2017;353:523\u2013528.","journal-title":"Am J Med Sci"},{"key":"7859_CR10","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/v14061325","volume":"14","author":"C Dietz","year":"2022","unstructured":"Dietz C, Maasoumy B. Direct-acting antiviral agents for hepatitis C virus infection\u2014From drug discovery to successful implementation in clinical practice. Viruses 2022;14:1325.","journal-title":"Viruses"},{"key":"7859_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/ecco-jcc\/jjz159","volume":"14","author":"E Rojo","year":"2020","unstructured":"Rojo E, Chaparro M, Garc\u00eda-Buey L. Efficacy and safety of glecaprevir\/pibrentasvir in a patient with HCV-induced porphyria cutanea tarda receiving vedolizumab for Crohn\u2019s disease. J Crohns Colitis 2020;14:567\u2013568.","journal-title":"J Crohns Colitis"},{"key":"7859_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/apt.15703","volume":"51","author":"L Sastre","year":"2020","unstructured":"Sastre L, To-Figueras J, Lens S et al. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther 2020;51:968\u2013973.","journal-title":"Aliment Pharmacol Ther"},{"key":"7859_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/bjd.13376","volume":"171","author":"P Aguilera","year":"2014","unstructured":"Aguilera P, Laguno M, To-Figueras J. Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda. Br J Dermatol 2014;171:1595\u20131596.","journal-title":"Br J Dermatol"},{"key":"7859_CR14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/jamadermatol.2016.3036","volume":"152","author":"Y Tong","year":"2016","unstructured":"Tong Y, Song YK, Tyring S. Resolution of porphyria cutanea tarda in patients with hepatitis C following ledipasvir-sofosbuvir combination therapy. JAMA Dermatol 2016;152:1393\u20131395.","journal-title":"JAMA Dermatol"},{"key":"7859_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12328-017-0772-x","volume":"10","author":"K Takata","year":"2017","unstructured":"Takata K, Shakado S, Sakamoto K et al. Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir\/sofosbuvir for hepatitis C. Clin J Gastroenterol 2017;10:459\u2013463.","journal-title":"Clin J Gastroenterol"},{"key":"7859_CR16","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1093\/jac\/dkx222","volume":"72","author":"B Bruzzone","year":"2017","unstructured":"Bruzzone B, Magnani O, Sticchi L et al. Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy. J Antimicrob Chemother 2017;72:2955\u20132958.","journal-title":"J Antimicrob Chemother"},{"key":"7859_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/ajg.2016.291","volume":"111","author":"F Drago","year":"2016","unstructured":"Drago F, Gasparini G, Marenco S, Picciotto A, Parodi A. Porphyrin elevation in a patient on treatment with simeprevir: could it be a possible explanation for simeprevir-associated photosensitivity? Am J Gastroenterol 2016;111:1368.","journal-title":"Am J Gastroenterol"},{"key":"7859_CR18","unstructured":"Bonkovsky H, Rudnick S, Faust D, et al. Direct-acting antivirals [DAA] are effective as sole treatment of porphyria cutanea tarda [PCT] with chronic hepatitis C [CHC]. Abstract D0490. Annual Meeting of the American College of Gastroenterology; Oct 21\u201326, 2022; Charlotte, NC."},{"key":"7859_CR19","unstructured":"Gilead. Harvoni: highlights of prescribing information. In:2020 Harvoni package insert."},{"key":"7859_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1023\/A:1013746828074","volume":"47","author":"NG Egger","year":"2002","unstructured":"Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419\u2013426.","journal-title":"Dig Dis Sci"},{"key":"7859_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archderm.139.3.309","volume":"139","author":"U St\u00f6lzel","year":"2003","unstructured":"St\u00f6lzel U, K\u00f6stler E, Schuppan D et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003;139:309\u2013313.","journal-title":"Arch Dermatol"},{"key":"7859_CR22","unstructured":"Rudnick S, Phillips J, Bonkovsky H. Porphyrias consortium of the rare diseases clinical research network. Familial porphyria cutanea tarda. In: Adam M, Everman D, Mirzaa G, Pagon R, Wallace S, eds. GeneReviews\u00ae[Internet]. Seattle (WA): University of Washington, Seattle 2013 Jun 6 [Updated 2022 Jun 9]."},{"key":"7859_CR23","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1073\/pnas.0700547104","volume":"104","author":"JD Phillips","year":"2007","unstructured":"Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 2007;104:5079\u20135084.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7859_CR24","unstructured":"Bonkovsky H, Rudnick S. Porphyria cutanea tarda. Merck Manual Web site. https:\/\/www.merckmanuals.com\/professional\/endocrine-and-metabolic-disorders\/porphyrias\/porphyria-cutanea-tarda#v15718555. Published 2020. Updated Dec 2020. Accessed 2022."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07859-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07859-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07859-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:38:39Z","timestamp":1744159119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07859-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7859"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07859-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the past 3\u00a0years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}